Niels Sharman

Senior Investment Manager

Niels Sharman

Senior Investment Manager

HTGF Munich

Niels Sharman has been supporting the life science investment team since November 2020. He holds a bachelor degree in biology from the Ludwig-Maximilians-University Munich and a master in management from the Technical University Munich. In the past he gained experience in the pharmaceutical industry and worked for two biotech start-ups.

Telefon:
+49 – (0) 228 – 82300 – 187

Portfolio

Posts & mentions

Blog
Blog
22. February 2024

Digital health investments: Road to success requires bold steps and an interdisciplinary approach

Since as far back as 2012, High-Tech Gründerfonds has been investing in start-ups that operate at the intersection between healthcare and digital solutions. In this interview, our Senior Investment Managers Louis Heinz (Digital Tech) and Niels Sharman (Life Sciences) share some insights into the synergies that arise from the HTGF team’s diverse perspectives and also give their take on where the sector stands in Germany and internationally. Louis Heinz and Niels Sharman, Senior Investme
 
Press
20. February 2024

Altavo concludes Series A for the development of its Artificial Voice

February 20, 2024 – Altavo, a startup in AI-based voice rehabilitation founded in 2021, successfully closed its Series A financing round on February 1, 2024. A European consortium led by OCCIDENT is investing € 5.0m in the development of Altavo’s novel Artificial Voice. Altavo’s Artificial Voice is a medical device designed to help voiceless people, for example after laryngectomy or during mechanical ventilation, regain their own, natural sounding voice. The proprietary “sil
 
Press
15. May 2023

Using an app to combat skin conditions: Nia Health receives millions in funding

The Berlin-based health tech start-up Nia Health receives 3.5 million euros in a seed financing round. The company originates from the Charité Universitätsmedizin Berlin and operates leading dermatology apps, including “Nia,” the most widely downloaded app for people with atopic dermatitis. The company has a network of renowned cooperation partners consisting of pharmaceutical companies, health insurance companies and clinics. The great potential lies above all in Nia
 
Press
1. September 2022

C-mo Medical Solutions raises €4.1 million aiming to transform cough monitoring

C-mo Medical Solutions is an award-winning start-up that is unravelling the potential of assessing cough towards improved diagnosis, treatment courses and disease management. The company has now raised 4.1€Mn in a seed round led by Boehringer Ingelheim Venture Fund. This investment will allow the company to bring its innovative cough-monitoring technology to the market. Lisbon, 1 September 2022 – C-mo Medical Solutions has announced today the closing of a 4.1€Mn seed investment roun
 
Press
31. March 2022

Improving ARDS treatment with digital twins: Ebenbuild secures seed financing round led by Bayern Kapital and High-Tech Gründerfonds

Munich/Bonn/Landshut, 31 March 2022 – Software start-up Ebenbuild has secured seven-figure funding as part of a seed financing round. Alongside lead investors High-Tech Gründerfonds and Bayern Kapital, the venture and growth capital organisation of the state of Bavaria, a number of well-known business angels also invested in the Munich-based HealthTech start-up, with the funding amounting to €2.5 million. Ebenbuild develops personalised lung simulation models based on patient data.